Whalesbook
BSE has approved the trading of 2.50 crore equity shares of Cian Healthcare Limited, representing a total face value of ₹25 crore. This approval stems from the company's Resolution Plan sanctioned by the National Company Law Tribunal (NCLT). Trading is scheduled to begin on April 2, 2026.
This step is vital for Cian Healthcare's revival following its insolvency proceedings. The company aims to enhance its public float and improve trading liquidity on the stock exchange, making shares more accessible for investors.
Cian Healthcare previously underwent the Corporate Insolvency Resolution Process (CIRP). The NCLT's approval of its Resolution Plan on December 18, 2025, marked the start of its restructuring phase, designed to turn the company around. The current trading approval is a direct outcome of this plan's successful implementation.
Of the 2.50 crore approved shares, 12,50,000 shares are allocated to public shareholders, and 2,37,50,000 shares are for promoters.
The company's past severe financial distress, stemming from its NCLT insolvency proceedings, means that the successful execution and long-term viability of the approved Resolution Plan are critical. Investors will also be evaluating market reception and the valuation of these newly listed shares. In the broader sector, companies like Poly Medicure Ltd. are prominent medical device manufacturers, but Cian Healthcare's recent NCLT resolution history sets it apart.
Looking ahead, investors will be monitoring trading volume and price movements from April 2, 2026. The company's future operational performance, financial results, and management's strategy for growth and expansion will also be key indicators to watch.